Browsing by Subject "Melphalan"
Now showing items 1-10 of 10
-
Article
Cancer of unknown primary origin
(1997)About 3 % of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic ...
-
Article
-
Article
-
Article
Late toxicity in survivors from adolescent cancers
(2007)Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates ...
-
Article
Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards
(2003)Research on systemic interventions in patients with advanced stage malignancies should be systematised with an emphasis on the absolute gain in survival for the median patient. Such information is most meaningful with ...
-
Article
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature
(2011)Introduction: Although more than 90% of melanomas have a cutaneous origin, occasionally it is discovered as a secondary deposit without evident primary site. The aim of this study was to systematically review published ...
-
Article
-
Article
Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data
(2006)Several chemotherapy and hormonal therapy regimens have been used in advanced endometrial cancer. In this review we have systematically evaluated the available data from randomized trials on survival. We searched MEDLINE, ...
-
Article
Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments
(2006)Background: Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer survival has improved in recent years, the magnitude of these incremental benefits ...
-
Article
Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors
(2010)Managing pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to ...